TANDEM DIABETES CARE INC: directors' dealings · United States · SEC (Form 4)

About TANDEM DIABETES CARE INC

Tandem Diabetes Care, Inc. is a U.S.-based medical technology company focused on insulin delivery and diabetes management. The stock, ticker TNDM, trades on the Nasdaq market in the United States. Headquartered in San Diego, California, Tandem develops and commercializes automated insulin delivery systems designed primarily for people with type 1 diabetes, while more recently extending certain products and software capabilities to adults with type 2 diabetes. The company’s model combines durable medical devices, proprietary software, connectivity, and ongoing supplies, giving it a platform-style business rather than a one-off device franchise. ([investor.tandemdiabetes.com](https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-launches-new-control-iq-automated-insulin/?utm_source=openai)) Tandem’s history is rooted in the early 2000s, when it began building a next-generation approach to insulin pump therapy out of Southern California. Over time, it evolved from an early-stage developer into a scaled commercial medtech company with manufacturing operations in San Diego and a growing international footprint. Today, the company describes itself as a global insulin delivery and diabetes technology company, reflecting both broader geographic reach and a more mature commercial organization. ([investor.tandemdiabetes.com](https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-announces-plans-new-corporate-headquarters/?utm_source=openai)) Its core product portfolio centers on the t:slim X2 insulin pump, the Tandem Mobi system, and Control-IQ / Control-IQ+ automated insulin delivery software. These solutions are designed to reduce the daily burden of diabetes management by integrating insulin delivery with continuous glucose monitoring and algorithm-driven automation. Tandem has also emphasized its infusion set offerings and its ability to connect with third-party CGM ecosystems, including Abbott and Dexcom, which is strategically important in a market where interoperability and patient convenience are increasingly decisive. ([investor.tandemdiabetes.com](https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-launches-new-control-iq-automated-insulin/?utm_source=openai)) From a competitive standpoint, Tandem operates in a concentrated and highly regulated diabetes technology market. Its differentiators are user experience, touchscreen/portable device design, automation software, and ecosystem partnerships. The company has positioned itself as more than a pump manufacturer, aiming to build an integrated care platform that can support patients, caregivers, and healthcare providers across the treatment journey. That positioning is relevant for investors because it supports potential recurring revenue from consumables, software updates, and service-related activities. ([tandemdiabetes.com](https://www.tandemdiabetes.com/about-us/?utm_source=openai)) Recent developments have been material. In March 2025, Tandem launched Control-IQ+ in the United States, and in February 2025 it received FDA clearance for Control-IQ+ for people with type 2 diabetes. The company also reported record quarterly sales in 2025 and continued to expand coverage and distribution, including pharmacy-benefit channels for Tandem Mobi. In February 2026, Tandem completed pricing for a private placement of $265 million of 0.00% convertible senior notes due 2032, underscoring a capital-markets step that may support strategic flexibility, operations, and ongoing product investment. ([investor.tandemdiabetes.com](https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-launches-new-control-iq-automated-insulin/?utm_source=openai))